Allarity Therapeutics (ALLR) Regains Nasdaq Compliance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
Allarity Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
May 20, 2024 8:00 AM EDTBoston (May 20, 2024)Allarity Therapeutics, Inc. (Allarity or the Company) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that it has received formal written notice from The Nasdaq Stock Market, LLCs Office of General Counsel (Nasdaq) that the Company has regained compliance with the minimum stockholders' equity requirement as set forth in Nasdaq Listing Rule 5550(b)(1) (the Equity Rule).
This confirmation follows the Companys successful efforts to cut operation costs and improve its balance sheet, including raising new equity and reducing outstanding liabilities. As a... More
